Optimising the use of mTOR inhibitors in renal transplantation

Area of Science:

• Nephrology
• Transplantation Immunology
• Pharmacology

Background:

• Renal transplantation is the primary treatment for end-stage renal failure.
• Long-term renal allograft survival remains a challenge, often limited by chronic allograft nephropathy and calcineurin inhibitor (CNI) nephrotoxicity.
• Patient mortality post-transplant is frequently due to cancer, cardiovascular disease, and infection.

Purpose of the Study:

• To evaluate the efficacy and safety of converting from calcineurin inhibitor (CNI)-based to mammalian target of rapamycin (mTOR) inhibitor-based immunosuppressive regimens in renal transplant recipients.
• To determine the optimal timing for conversion to mTOR inhibitor-based therapy.
• To assess the impact of mTOR inhibitor-based regimens on renal function, patient survival, and post-transplant complications.

Main Methods:

• Review of clinical trials investigating conversion from CNI-based to mTOR inhibitor-based immunosuppression.
• Analysis of data on renal function, graft survival, patient survival, and adverse events.
• Identification of the most effective time window for conversion post-transplant.

Main Results:

• Conversion to mTOR inhibitor-based regimens has shown success in improving renal function in the years following conversion.
• The optimal period for conversion appears to be between 1 and 6 months after renal transplantation.
• mTOR inhibitor-based regimens are associated with reduced rates of post-transplant malignancy and cytomegalovirus infection.

Conclusions:

• Switching to mammalian target of rapamycin (mTOR) inhibitors offers a promising alternative to calcineurin inhibitors (CNIs) in renal transplantation.
• Early conversion (1-6 months post-transplant) to mTOR inhibitor-based immunosuppression may improve renal function and reduce key mortality risks.
• Further long-term data are needed, but mTOR inhibitor-based regimens show potential for enhanced graft and patient survival by mitigating nephrotoxicity and specific complications.